Share on StockTwits

Research analysts at HC Wainwright assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) in a report released on Thursday, reports. The firm set a “buy” rating and a $3.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 156.41% from the stock’s previous close.

Aeterna Zentaris (NASDAQ:AEZS) opened at 1.17 on Thursday. Aeterna Zentaris has a 52-week low of $0.99 and a 52-week high of $1.91. The stock has a 50-day moving average of $1.14 and a 200-day moving average of $1.2. The company has a market cap of $66.1 million and a price-to-earnings ratio of 76.88.

Aeterna Zentaris (NASDAQ:AEZS) last released its earnings data on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.30) by $0.22. Analysts expect that Aeterna Zentaris will post $-0.83 EPS for the current fiscal year.

Aeterna Zentaris Inc (NASDAQ:AEZS) is a drug development company specialized in oncology and endocrine therapy.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.